Challenges of immune responses in gene replacement therapy.
Permanent gene replacement therapy using viral carriers such as adenovirus or adenovirus-associated virus vectors has failed thus far in human patients, in part due to immune responses to antigens of the viral carrier, a problem that has remained underappreciated and thus largely unaddressed.